Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,014 people get IBB articles and Market Currents by email alert.
Get email alerts on IBB »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
Big Pharma's Potential Consumer Growth AvenueJessica King Holden • Tue, Feb 7, 2012 -
-
-
-
Re-Evaluating Your Healthcare Exposure: A Sector ETF OverviewMorningstar • Thu, Mar 4, 2010
-
-
iShares Biotech Index ETF: The Best Way to Invest in BiotechSmart Profits Report • Wed, Apr 16, 2008 -
Biotech ETF's Diversity Reduces RiskTom Lydon • Thu, Jan 18, 2007 -
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
2 Buys, 1 Sell In This Year's Biotech SurgeRichard Cox • Thu, May 30 -
-
Positive Prognosis For Biotech ETFsTom Lydon • Mon, May 13
-
-
-
-
-
-
-
-
-
-
-
3 Stocks With Positive Upgrades And How To InvestNick Chiu • Thu, Feb 28
-
-
-
Are Global Health Care ETFs Worth Prescribing?Benzinga • Fri, Feb 22
There are no Transcripts on IBB.
-
at CNBC.com (Jun 7, 2013)
-
at MarketWatch.com (Jun 3, 2013)
-
at MarketWatch.com (May 21, 2013)
-
at MarketWatch.com (Sep 11, 2012)
-
at MarketWatch.com (Jul 31, 2012)
-
at MarketWatch.com (Jul 17, 2012)
-
at MarketWatch.com (Jul 3, 2012)
-
at MarketWatch.com (Jun 19, 2012)
-
at CNBC.com (Jan 30, 2012)
-
at MarketWatch.com (Jul 1, 2011)
-
at MarketWatch.com (Jun 20, 2011)
-
at MarketWatch.com (May 20, 2011)
-
at CNBC.com (Mar 30, 2011)
-
at CNBC.com (Mar 30, 2011)
-
at CNBC.com (Oct 25, 2010)
-
at CNBC.com (Jul 29, 2010)
-
at CNBC.com (Jul 2, 2010)
-
at CNBC.com (Jun 15, 2010)
IBB vs. ETF Alternatives
IBB Description
The iShares Nasdaq Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index<sup>®</sup>.
See more details on sponsor's website
See more details on sponsor's website
Sector: Healthcare
Country: United States
Key Info
- In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
- Asset Class Performance: Sectors
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
- Thursday, April 11, 2:08 PM Healthcare and biotech ETFs continue to churn higher again today, hitting new 52-week highs across the board: Health Care SPDR (XLV +1%), Vanguard Health Care ETF (VHT +0.9%), iShares Dow Jones US Healthcare (IYH +0.9%),. Biotech ETF iShares NASDAQ Biotechnology Index (IBB +1.3%). 1 Comment [Healthcare, On the Move]
- Thursday, March 28, 4:24 PM Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 1 Comment [Healthcare]
- Monday, May 14, 2012, 11:45 AM Biotech ETFs are near all-time highs despite overall market weakness, due to successful trials - e.g. for Vertex's (VRTX) cystic fibrosis treatment - and because some investors are betting on deals occurring. One ETF that is doing particularly well this year is iShares Nasdaq Biotech (IBB). Others include XBI, FBT and BBH. 6 Comments [Healthcare]
- Monday, March 12, 2012, 12:07 PM Shares of Anthera Pharmaceuticals (ANTH -52.1%) can't stop the freefall that was triggered by Friday's announcement that it's canceling its late-stage trial of its experimental treatment for heart disease. Adam Feuerstein eyes the recent carnage with a number of biotech names to conclude that "fail" is now re-entering the lexicon of investors in the sector. Comment! [On the Move, Healthcare, Quick Ideas]
- Monday, January 23, 2012, 3:48 PM Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%. Comment! [Healthcare, On the Move]
- Wednesday, January 18, 2012, 2:39 PM Josh Brown notices a "massive multi-year breakout" in biotech stocks (IBB +0.9%), with further gains likely as large pharmas continue to acquire the smaller firms so long as their own R&D departments are starving. "They have tons of cash and a burning desire to add pipeline - which makes almost every publicly-traded biotech a target for someone." Comment! [Healthcare]
- Wednesday, September 7, 2011, 11:36 AM The biotech industry looks ripe for more gains after posting a second consecutive year of profits and seeing M&A activity heat up, says Karvy Global Services. Crunching the numbers reveals 8 stocks with implied upside potential based on quarterly results and analyst recommendations. Picks: HITK, CELG, DNDN, WX, TEVA, ILMN, CRL, BIIB. Comment! [Quick Ideas]
- Thursday, August 4, 2011, 4:05 PM Dendreon (DNDN -67.4%) takes down an entire industry, with the Amex Biotech index falling an astonishing 10.4%. "Biotech risk takers burned on this one might be less risk tolerant going forward," one analyst explains. "The biotech group does work like that, especially for product failures." IBB -7.9%. XBI -9.8%. Comment! [Healthcare, On the Move, Top Stories]
- Monday, June 27, 2011, 11:11 AM XOMA soars 33% after announcing the discovery of two new classes of fully human monoclonal antibodies at the American Diabetes Association 71st Scientific Sessions in San Diego. Comment! [Healthcare, On the Move]
- Thursday, June 23, 2011, 4:17 PM Repligen's (RGEN +5%) jumps after its spinal muscular atrophy drug gets a fast-track designation from the FDA, and a postive opinion for orphan status from the European Medicines Agency. Comment! [Healthcare]
- Wednesday, June 22, 2011, 9:52 AM Achillion Pharmaceuticals (ACHN +11.5%) jumps after pricing its secondary offering at $5.90, a 1.8% discount to yesterday's close. The company plans to use the $52M it raised to bring its new line of hepatitis-c drugs to market. Comment! [Healthcare, On the Move]
- Monday, June 20, 2011, 4:20 PM Biogen-IDEC (BIIB +4.1%) closes at the top of the S&P leader board after ISI Group ups it to Buy, citing a strong pipeline, and noting its new BG-12 multiple-sclerosis pill can double earnings over the next three to four years. Comment! [Healthcare, On the Move]
- Friday, June 17, 2011, 8:51 AM Vivus (VVUS) reports positive results for phase III testing of its erectile dysfunction drug Avanafil. The study is the last in a series to evaluate the drug's safety and efficacy in treating ED in patients who have undergone a radical prostatectomy. Shares +4% premarket. Comment! [Healthcare, On the Move]
- Monday, March 7, 2011, 7:43 AM Sanofi (SNY) extends its offer for the outstanding shares of Genzyme (GENZ) to April 1 from March 16. Meanwhile, other biotech firms focused on rare diseases say the Sanofi-Genzyme deal puts many peers into play as takeover targets. Comment!
-
Saturday, October 30, 2010, 4:58 PM
In a major policy reversal, the DoJ filed an amicus brief late yesterday saying human DNA and other genes shouldn't be eligible for patents. It's unclear whether the Patent Office will adopt the position, which could potentially force some biotech firms to change the way they develop drugs.
Comment!
-
Ypa Finance
$XLF is sector ETF #2 in our Tactical Allocation ranking. $IBB is #1. http://bit.ly/15ZIU78 - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
Dr. Kris: If you're in any of these, you might want to start putting in a trailing (mental) stop/loss; lighten up; or protect position.
-
-
- View all 0 replies
-
Justin M. Hall
3/21/12 2:05P ET: [ IBB ] When IBB hits $122, it's time to get short. Consider playing BIS. I continue to like this play at/below $24. - View all 5 replies
-
Justin M. Hall: It might require some work. We did very well with it last year. No BS. I like BIS right here and now.
-
Justin M. Hall: [BIS] Going forward, I firmly believe it'll prove to be a solid bet. So, let's see how it plays out.
-
- View all 0 replies
-
Justin M. Hall
8/6/11 12A ET: (CBST, SPPI, IBB, BIS, XBI) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg - View all 0 replies
-
Justin M. Hall
8/4/11 2:40P ET: BIOTECH CORRECTION Called Back in May-June 2011 [Rx Investors.com] (IBB, BIS, XBI, VRTX, DNDN) http://seekingalpha.com/p/4bsg - View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
Dr. Kris: If you're in any of these, you might want to start putting in a trailing (mental) stop/loss; lighten up; or protect position.
-
-
Justin M. Hall
3/21/12 2:05P ET: [ IBB ] When IBB hits $122, it's time to get short. Consider playing BIS. I continue to like this play at/below $24. - View all 5 replies
-
Justin M. Hall: It might require some work. We did very well with it last year. No BS. I like BIS right here and now.
-
Justin M. Hall: [BIS] Going forward, I firmly believe it'll prove to be a solid bet. So, let's see how it plays out.